ConductScience.org, home

Paper36968951

Impact of ompk36 genotype and KPC subtype on the in vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam against KPC-producing K. pneumoniae clinical isolates.

Rogers TM and 6 others. JAC Antimicrob Resist, 2023. Cited by 19 papers, by iCite.

Cite this record

ConductScience Library. Impact of ompk36 genotype and KPC subtype on the in vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam against KPC-producing K. pneumoniae clinical isolates. Papers, record 36968951. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36968951

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Impact of ompk36 genotype and KPC subtype on the in vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam against KPC-producing K. pneumoniae clinical isolates.
PubMed
Journal
JAC Antimicrob Resist
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
19
iCite
Relative citation ratio, by iCite
2.91
iCite
Revised in PubMed
2025-02-27
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rogers TMTara M
2Kline EGEllen G
3Griffith MPMarissa P
4Jones CEChelsea E
5Rubio AMAbigail M
6Squires KMKevin M
7Shields RKRyan Khttps://orcid.org/0000-0001-9794-5665

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R03 AI144636NIAID NIH HHSUnited StatesR03AI144636PubMedNIH RePORTER
R21 AI151363NIAID NIH HHSUnited StatesR21AI151363PubMedNIH RePORTER

Download CSV of grants

References34

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
126349830Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects.Antimicrob Agents Chemother2015https://conductscience.org/library/papers/26349830PubMed
234901302Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections.Open Forum Infect Dis2021https://conductscience.org/library/papers/34901302PubMed
335065702Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.Lancet2022https://conductscience.org/library/papers/35065702PubMed
429914955Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants.Antimicrob Agents Chemother2018https://conductscience.org/library/papers/29914955PubMed
529038260Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae.Antimicrob Agents Chemother2017https://conductscience.org/library/papers/29038260PubMed
635373297Dynamic evolution of imipenem/relebactam resistance in a KPC-producing Klebsiella pneumoniae from a single patient during ceftazidime/avibactam-based treatments.J Antimicrob Chemother2022https://conductscience.org/library/papers/35373297PubMed
723459476Characterization of porin expression in Klebsiella pneumoniae Carbapenemase (KPC)-producing K. pneumoniae identifies isolates most susceptible to the combination of colistin and carbapenems.Antimicrob Agents Chemother2013https://conductscience.org/library/papers/23459476PubMed
836154170In Vitro Mechanisms of Resistance Development to Imipenem-Relebactam in KPC-Producing Klebsiella pneumoniae.Antimicrob Agents Chemother2022https://conductscience.org/library/papers/36154170PubMed
933820773In Vitro Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam.Antimicrob Agents Chemother2021https://conductscience.org/library/papers/33820773PubMed
1026169413
Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae.
Antimicrob Agents Chemother2015https://conductscience.org/library/papers/26169413PubMed
1128630202Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae.Antimicrob Agents Chemother2017https://conductscience.org/library/papers/28630202PubMed
1223939888Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin.Antimicrob Agents Chemother2013https://conductscience.org/library/papers/23939888PubMed
1333106864
Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).
Clin Infect Dis2021https://conductscience.org/library/papers/33106864PubMed
1428848018Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae.Antimicrob Agents Chemother2017https://conductscience.org/library/papers/28848018PubMed
1536374023Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints.Antimicrob Agents Chemother2022https://conductscience.org/library/papers/36374023PubMed
1634923128
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine).
Clin Microbiol Infect2022https://conductscience.org/library/papers/34923128PubMed
1735416711Increased blaKPC Copy Number and OmpK35 and OmpK36 Porins Disruption Mediated Resistance to Imipenem/Relebactam and Meropenem/Vaborbactam in a KPC-Producing Klebsiella pneumoniae Clinical Isolate.Antimicrob Agents Chemother2022https://conductscience.org/library/papers/35416711PubMed
1831477712OmpK36-mediated Carbapenem resistance attenuates ST258 Klebsiella pneumoniae in vivo.Nat Commun2019https://conductscience.org/library/papers/31477712PubMed
1932151332Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study.Lancet Infect Dis2020https://conductscience.org/library/papers/32151332PubMed
2030617090Effects of KPC Variant and Porin Genotype on the In Vitro Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae.Antimicrob Agents Chemother2019https://conductscience.org/library/papers/30617090PubMed

See all 34 referencesDownload CSV of references

Cited by14

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 19 citations.

PMIDTitleJournalYearIn PapersSource
42267316Carbapenemases: epidemiology, detection and management in a changing global landscape.JAC Antimicrob Resist2026https://conductscience.org/library/papers/42267316PubMed
42136902Successful Treatment with Imipenem/Cilastatin/ Relebactam of a Polymicrobial Bacteremia due to Meropenem/Vaborbactam-Resistant KPC-Kp and Enterococcus Faecalis.Mediterr J Hematol Infect Dis2026https://conductscience.org/library/papers/42136902PubMed
42106608Genomic and molecular characterisation of a KPC-producing Klebsiella pneumoniae clinical isolate resistant to meropenem-vaborbactam, imipenem-relebactam, and ceftazidime-avibactam.BMC Genom Data2026https://conductscience.org/library/papers/42106608PubMed
41892432Novel Insights into Carbapenem Resistance: Mechanisms, Diagnostics, and Future Directions.Antibiotics (Basel)2026https://conductscience.org/library/papers/41892432PubMed
41777542First identification of an ST11-KL64 hypervirulent Klebsiella pneumoniae strain coproducing KPC-2 and NDM-1 with an OmpK36 GD mutation.Front Microbiol2026https://conductscience.org/library/papers/41777542PubMed
41608681Molecular resistance mechanisms to newly approved antibiotics (2017-2025) in WHO priority pathogens.Front Microbiol2025https://conductscience.org/library/papers/41608681PubMed
41436714Emergence of resistance to novel β-lactam/β-lactamase inhibitor combinations in KPC-producing Klebsiella pneumoniae: clinical and genomic insights from consecutive bloodstream infections.Infection2026https://conductscience.org/library/papers/41436714PubMed
41258724Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combating carbapenem-resistant Enterobacter cloacae.Antimicrob Agents Chemother2025https://conductscience.org/library/papers/41258724PubMed
40223126Activity of imipenem/relebactam against KPC-producing Klebsiella pneumoniae and the possible role of Ompk36 mutation in determining resistance: an Italian retrospective analysis.Ann Clin Microbiol Antimicrob2025https://conductscience.org/library/papers/40223126PubMed
39239090
Emergence of high-level aztreonam-avibactam and cefiderocol resistance following treatment of an NDM-producing Escherichia coli bloodstream isolate exhibiting reduced susceptibility to both agents at baseline.
JAC Antimicrob Resist2024https://conductscience.org/library/papers/39239090PubMed
38426743In vitro activity of meropenem-vaborbactam plus aztreonam against metallo-β-lactamase-producing Klebsiella pneumoniae.Antimicrob Agents Chemother2024https://conductscience.org/library/papers/38426743PubMed
37901589Mutations in ompK36 differentially impact in vitro synergy of meropenem/vaborbactam and ceftazidime/avibactam in combination with other antibiotics against KPC-producing Klebsiella pneumoniae.JAC Antimicrob Resist2023https://conductscience.org/library/papers/37901589PubMed
37887222Ceftazidime/Avibactam and Meropenem/Vaborbactam for the Management of Enterobacterales Infections: A Narrative Review, Clinical Considerations, and Expert Opinion.Antibiotics (Basel)2023https://conductscience.org/library/papers/37887222PubMed
37764198A Whole-Genome Sequencing-Based Approach for the Characterization of Klebsiella pneumoniae Co-Producing KPC and OXA-48-like Carbapenemases Circulating in Sardinia, Italy.Microorganisms2023https://conductscience.org/library/papers/37764198PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
IS5100190985PubTator's text mininghttps://conductscience.org/library/genes/100190985NCBI Gene
UBAC110422PubTator's text mininghttps://conductscience.org/library/genes/10422NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36968951

GET https://conductscience.org/api/papers/v1/36968951/references?page=2